Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physical Frailty, Self-Care Behaviors, and 6-Month Clinical Outcomes Among Adults With Heart Failure.

The Journal of cardiovascular nursing·2026
Same author

Comparison Between Helpful and Missing Resources Identified by Patients with End-Stage Liver Disease and Their Caregivers: A Content Analysis.

Nursing reports (Pavia, Italy)·2026
Same author

Distinct Patterns of Dyadic Mental Health in Patients with End-Stage Liver Disease and Their Care Partners.

Healthcare (Basel, Switzerland)·2026
Same author

Multidimensional experience of pain in adults with cirrhosis: A qualitative descriptive study.

Canadian journal of pain = Revue canadienne de la douleur·2025
Same author

Longitudinal changes in physical and psychological outcomes in spousal vs. non-spousal caregivers for patients with end-stage liver disease.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2025
Same author

Association of spirituality and quality of life in cancer survivors: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025

Related Experiment Video

Updated: Jun 9, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

End-stage liver disease: challenges and practice implications.

Lissi Hansen1, Anna Sasaki, Betsy Zucker

  • 1School of Nursing, Oregon Health & Science University, SN 6S, 3455 South West US Veterans Hospital Road, Portland, OR 97239, USA. hansenli@ohsu.edu

The Nursing Clinics of North America
|September 1, 2010
PubMed
Summary
This summary is machine-generated.

End-stage liver disease (ESLD) presents significant end-of-life challenges for patients and families. This article details these difficulties, including ascites and pain, to improve healthcare for those with advanced liver disease.

Related Experiment Videos

Last Updated: Jun 9, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatology
  • Palliative Care
  • Internal Medicine

Background:

  • End-stage liver disease (ESLD) is a leading cause of death in working-aged Americans.
  • Limited documentation exists on the end-of-life challenges faced by individuals with progressive ESLD.
  • Understanding these challenges is crucial for improving patient care and support systems.

Purpose of the Study:

  • To identify and describe specific end-of-life challenges associated with end-stage liver disease (ESLD).
  • To explore the implications of these challenges for patients, their families, and healthcare providers.
  • To illustrate disease progression and associated difficulties through a case study.

Main Methods:

  • Literature review and synthesis of documented end-of-life challenges in ESLD.
  • Identification of key clinical manifestations and complications.
  • Presentation of a case study to exemplify patient and family experiences.

Main Results:

  • Identified key challenges include ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, malnutrition, altered drug metabolism, renal insufficiency, hyponatremia, hepatocellular carcinoma, and pain.
  • These complications significantly impact patient quality of life and require complex management.
  • The case study highlights the multifaceted difficulties encountered by patients, families, and healthcare teams.

Conclusions:

  • Addressing the specific end-of-life challenges in ESLD is critical for comprehensive patient care.
  • Healthcare providers need to be aware of and prepared for these complex issues.
  • Further research and improved support strategies are needed to enhance the end-of-life experience for ESLD patients and their families.